Comparative Pharmacology
Head-to-head clinical analysis: CHLORMERODRIN HG 197 versus MPI INDIUM DTPA IN 111.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORMERODRIN HG 197 versus MPI INDIUM DTPA IN 111.
CHLORMERODRIN HG 197 vs MPI INDIUM DTPA IN 111
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Radioactive mercury isotope that emits gamma rays; distributes in renal parenchyma, allowing scintigraphic imaging of kidneys. The mercury moiety binds to sulfhydryl groups in renal tubules, concentrating in functioning renal tissue.
Indium In-111 DTPA is a radiopharmaceutical that emits gamma radiation, used for imaging. DTPA chelates indium-111 and, after administration, distributes in the extracellular fluid and is cleared by glomerular filtration, allowing cisternography and renal imaging.
Chlormerodrin Hg 197 is administered intravenously as a single dose of 10 µCi (0.37 MBq) for renal imaging. The typical adult dose is 10-30 µCi (0.37-1.11 MBq) IV.
Adult: 18.5 MBq (0.5 mCi) administered intravenously as a single dose for renal imaging.
None Documented
None Documented
Terminal elimination half-life approximately 3 days (72 hours) in patients with normal renal function; prolonged in renal impairment.
Terminal half-life: 2.5-4.0 hours (plasma); prolonged in renal impairment.
Renal: >90% of absorbed dose excreted in urine within 24 hours; biliary/fecal: <5%.
Renal: 90% within 24 hours via glomerular filtration; minimal biliary/fecal (<5%).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical